Smallpox Vaccine Trial Results

Article

3 SEPTEMBER - Acambis has completed a Phase 1 trial of it's smallpox vaccine, ACAM1000.

Smallpox vaccine trial resultsCambridge, UK and Cambridge, Massachusetts - 3 September 2002 - Acambis plc("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that it has completed a PhaseI trial of its smallpox vaccine, ACAM1000. The trial tested the safety, tolerability and immunogenicity of ACAM1000 andDryvax®, the smallpox vaccine that was widely used during the worldwidesmallpox eradication programme. In the 60-subject, randomised, double-blindtrial, 30 subjects were given the standard dose of Dryvax® and 30 were givenan equivalent dose of ACAM1000. The currently accepted indication of protective immunogenicity in the caseof smallpox vaccination is the development of a pock-mark on the skin, knownas a "take". This was the primary endpoint of the trial. A "take" was seenwithin 10 days after vaccination in 100% of ACAM1000-treated subjects and97% of Dryvax®-treated subjects. The size and appearance of the "takes"were identical across treatment groups. No serious or unexpected adverseevents were reported in the ACAM1000 group, whereas one subject in theDryvax® group developed a non-healing pock at the site of inoculation. The results of this Phase I trial will be presented by Dr Thomas Monath,Chief Scientific Officer, at a meeting of the G7 Global Health SecurityAction Group being held at the Paul-Ehrlich-Institut in Langen, Germany on5-6 September.Following these encouraging results, a second, open-label trial has beeninitiated in which 70 subjects are being given ACAM1000 to test further thevaccine's safety and immunogenicity. Results from this second trial areexpected to be available shortly.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.